news – pharmaceutical daily news

AstraZeneca’s Imfinzi improves overall survival in trial for cell lung cancer

AstraZeneca and MedImmune, its global biologics research and development arm, on Friday reported positive overall survival (OS) results for the

Eli Lilly said Thursday its senior vice president and president of Lilly Oncology, and the member of the company’s executive

Novartis’s Sandoz has secured European Commission’s approval for biosimilar Zessly, the company said Thursday.

People treated with Saxenda for weight management lost an average of 8.1 kg after six months in a real-world clinical

Eli Lilly said Tuesday that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz injection 80 mg/mL to

Circassia Pharmaceuticals showed positive clinical data from two studies of Tudorza and Duaklir, nearing the a deal with AstraZeneca in the United

The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared 4D pharma’s Clinical Trial Application for MRx0518, a live biotherapeutic

The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults

The US Food and Drug Administration (FDA) has approved Novartis’s and Amgen’s Aimovig (erenumab) for the preventive treatment of migraine in

Sanofi’s pivotal Phase 3 test of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents met its primary and key secondary

How monoclonal antibodies can fight emerging infectious diseases?
Monoclonal antibodies (mAbs) — preparations of a specific type of antibody designed to bind to a single target — have shown promise in the fight against cancer and autoimmune diseases, a new article
Counterfeited products risk to people seeking help on the internet
As personalised medicines become more and more prominent in today’s industry, Professor Phillipe Arnaud – Chief of Pharmacy Department at Bichat-Claude Bernard Hospital and ANSM Expert – believes that customer feedback will be
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
Novartis and the Bill & Melinda Gates Foundation have formed an alliance to advance development of Novartis’ drug candidate KDU731 for the treatment of cryptosporidiosis. Diarrheal diseases are one of the leading causes